Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

Overview of attention for article published in Frontiers in Pharmacology, August 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 9,638 followers.

RT @DueDoctor: ☑ Low dose $KPTI selinexor ☑ Increasing potential disease states for treat

04 Aug 2023

Reply Repost Favourite

☑ Low dose $KPTI selinexor ☑ Increasing potential disease states for treat

04 Aug 2023

Reply Repost Favourite

@komatinskys @DueDoctor https://t.co/LuqGo9H0kI

04 Aug 2023

Reply Repost Favourite

New Research: Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma #pharmacology https://t.co/yQ4SbQYZeV

04 Aug 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.